Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
書誌事項
- 公開日
- 2022-09
- 権利情報
-
- https://www.elsevier.com/tdm/userlicense/1.0/
- https://www.elsevier.com/legal/tdmrep-license
- http://creativecommons.org/licenses/by-nc-nd/4.0/
- DOI
-
- 10.1016/s1470-2045(22)00487-9
- 公開者
- Elsevier BV
この論文をさがす
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 23 (9), 1133-1144, 2022-09
Elsevier BV